



Announcement Summary

Entity name

ANATARA LIFESCIENCES LTD

Date of this announcement

Friday August 09, 2024

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
ANRAR	PERFORMANCE RIGHTS	886,312	09/08/2024

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

ANATARA LIFESCIENCES LTD

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ABN

Registration number

41145239872

1.3 ASX issuer code

ANR

1.4 The announcement is

New announcement

1.5 Date of this announcement

9/8/2024



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

ANRAR : PERFORMANCE RIGHTS

Date the +securities the subject of this notification were issued

9/8/2024

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
Simon Erskine / Chief Development Officer	Simon Erskine	749,250
Michael West / Chief Scientific Officer	Michael West	137,062

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

<https://anataralifesciences.com/investors/corporate-governance>

Any other information the entity wishes to provide about the +securities the subject of this notification

No consideration payable. The Performance Rights were granted under the FY24 STI entitlement rather than payment of a cash bonus. The exercise price of the Performance Right is NIL and vest on the issue date.

Issue details

Number of +securities

886,312

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

ASX +security code and description	Total number of +securities on issue
ANR : ORDINARY FULLY PAID	192,893,727

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
ANRAR : PERFORMANCE RIGHTS	2,704,100
ANRAQ : OPTION EXPIRING 25-NOV-2025 EX \$0.203	300,000
ANRAO : OPTION EXPIRING 14-NOV-2025 EX \$0.225	1,350,000
ANRAW : OPTION EXPIRING 08-JUL-2028 EX \$0.10	4,500,000
ANRAT : OPTION EXPIRING 11-DEC-2025 EX \$0.07	23,352,758
ANRAN : OPTION EXPIRING 18-AUG-2025 EX \$0.2256	20,000
ANRAV : OPTION EXPIRING 06-MAY-2027 EX \$0.10	2,000,000



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13